UCB today announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a potential first in class, small molecule,
UCB Announces Global Partnership To Bring Disease-Modifying Therapies To People Living With Parkinson's Disease - read this article along with other careers information, tips and advice on BioSpace
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
/PRNewswire/ UCB today announced that it has entered into a global co-development and co-commercialization agreement with Novartis covering UCB0599, a.
UCB to partner with Novartis on development of UCB0599 with an opt-in to develop UCB7853, two innovative and potentially disease-modifying investigational assets in Parkinson's disease